Literature DB >> 12809321

A potential error in evaluating cancer screening: a comparison of 2 approaches for modeling underlying disease progression.

Sue J Goldie1, Karen M Kuntz.   

Abstract

BACKGROUND: Evaluating cancer screening often requires modeling the underlying disease process and not observed disease, particularly in the absence of direct evidence linking screening to a survival benefit.
METHODS: To illustrate a potential error in modeling disease progression among healthy persons with a history of a precancerous lesion, we constructed 2 models with 4 basic health states (disease free, presence of a precancerous lesion, presence of cancer, dead), calibrated to predict the same 10-year cancer incidence. We assumed a homogeneous cohort enters each model free of disease, the probability of developing a precancerous lesion was greater for patients with a history of a prior lesion, and the screening test was perfect and riskless. In one model, we assigned a higher transition probability from a precancerous lesion to cancer in those with a history of a previously removed lesion; in the other, we assumed it was equal to those with no history.
RESULTS: Using the 1st model, life expectancy without screening was 2.4 months longer than with screening. This error did not occur using the 2nd model, in which the transition from precancerous lesions to cancer was not conditional on a history of a lesion. This modeling error's magnitude was examined under a variety of assumptions.
CONCLUSIONS: We have identified an important error to avoid when modeling the underlying disease process in evaluating screening programs for cancers associated with precancerous states.

Entities:  

Mesh:

Year:  2003        PMID: 12809321     DOI: 10.1177/0272989X03023003005

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  4 in total

1.  Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women.

Authors:  Anna-Barbara Moscicki; J Thomas Cox
Journal:  J Low Genit Tract Dis       Date:  2010-01       Impact factor: 1.925

2.  Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio.

Authors:  Fernando Alarid-Escudero; Karen M Kuntz
Journal:  Pharmacoeconomics       Date:  2020-03       Impact factor: 4.981

3.  Potential impact of antiretroviral therapy and screening on cervical cancer mortality in HIV-positive women in sub-Saharan Africa: a simulation.

Authors:  Julius Atashili; Jennifer S Smith; Adaora A Adimora; Joseph Eron; William C Miller; Evan Myers
Journal:  PLoS One       Date:  2011-04-04       Impact factor: 3.240

4.  Pharmacogenomics Bias - Systematic distortion of study results by genetic heterogeneity.

Authors:  Uwe Siebert; Gaby Sroczynski; Vera Zietemann
Journal:  GMS Health Technol Assess       Date:  2008-04-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.